← Retour à la une
États-Unis · Plateformes & données · The Motley Fool

Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027

Publié par The Motley Fool · États-Unis il y a 26 min
Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027
Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027 · The Motley Fool

Résumé détaillé

Pfizer remains deeply unloved on Wall Street, but it is slowly turning a corner.

Pfizer (PFE -0.51%) faces a large patent cliff, and investors worry it won't be able to offset the revenue it loses as older drugs face generic competition. That's a problem, but the drugmaker is aware of it and is making important strides in its efforts to address the issue. The big story, however, is that this issue is pretty normal for a drug company.

In fact, revenue from recently launched and acquired drugs rose 32% in the third quarter of 2026. That shows the pharmaceutical giant's efforts are bearing fruit. But there's more reason to be excited, including the company's strong balance sheet, its large dividend, and management's commitment to continue paying that dividend. Here's what you need to know.

One of the biggest worries about Pfizer is its upcoming patent expirations. Two big ones are Eliquis in 2028 and Vyndamax in 2031. But patent expirations are a normal part of the pharma sector. And research and development efforts in the highly technical and intensely competitive healthcare sector don't always align perfectly with a company's patent expiration schedule. It's just a fact of life.

The 32% revenue growth Pfizer achieved from launched and acquired products is evidence that the company is seeing some success in its efforts to address the issue. And it sets up three more reasons to consider buying the stock.

Pfizer ended the third quarter of 2026 with $1.8 billion in cash and $12.4 billion in short-term investments. That gives the company significant firepower to support its business through this patent-expiration cycle. In fact, the company's cash hoard is slightly higher than at the start of the year, so it isn't rapidly burning through its savings.

Despite the company's results with new drugs and its financial strength, investors are deeply negative on Pfizer's stock. That's highlighted by its huge 6.1% dividend yield as of this writing.

The negativity highlighted by the elevated yield is echoed by more traditional valuation metrics.

Given the lofty…

Début de l'article, extrait de The Motley Fool. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur The Motley Fool Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com)

À lire aussi